viewHalma PLC

Halma PLC - COVID-19 Update

RNS Number : 2609K
Halma PLC
21 April 2020


Halma today releases an update regarding the impact of the COVID-19 pandemic.


Full Year Results announcement and AGM


We continue to expect our adjusted profit before tax for the year ended 31 March 2020 to be in a range of £265 million to £270 million, in line with the guidance given in our scheduled Trading Update on 19 March 2020. We expect revenues to be approximately £1,330 million and year-end net debt (excluding the impact of IFRS16) to be approximately £320 million.


We expect to release our preliminary results on 14 July 2020. This date has been agreed in consultation with our auditors, PricewaterhouseCoopers LLP, and reflects the challenges of completing the audit of a geographically dispersed group given the travel restrictions and enhanced safe-working practices currently in place. Accordingly, our AGM will take place in early September 2020.


Balance sheet and liquidity


Our financial position remains robust with committed facilities totalling approximately £750 million (at current exchange rates). The earliest maturity in these facilities is for £74 million (at current exchange rates) in January 2021, with the remaining maturities from 2023 onwards. The financial covenants on these facilities are for leverage (net debt/adjusted EBITDA) to not be more than three times and for adjusted interest cover to be not less than four times.


Currently, we do not intend to utilise the UK government's COVID Corporate Financing Facility, although we have taken the prudent step of confirming Halma's eligibility in principle, subject to establishing an appropriate commercial paper programme.


The impact of COVID-19 challenges and our responses


Halma has a long track record of successfully adapting to societal shifts and changes in markets. We believe that our agile business model, and our focus on critical safety, health, and environmental market niches, will enable us to perform relatively resiliently and contribute to the global efforts to deal with COVID-19.




Partnering with our central and regional COVID-19 support groups, the first of which was established in January 2020 following the initial outbreak in China, each of our companies is implementing an operating plan to suit its market and local circumstances.


Our 43 operating companies have a total of 54 principal operating facilities spread across the UK, the USA, Mainland Europe and Asia. Over 30 of our companies deliver critical safety, healthcare and environmental protection solutions and have a mandate or permission from regional or national authorities to continue to operate during shutdown restrictions.


Currently, following the re-opening of our fire safety business in Italy last week, there are only two facilities, in California and Tunisia, that are closed due to government shutdown restrictions. However, all our businesses are having to address their specific supply chain and distribution challenges that are being caused by the pandemic, as well as responding to the similar challenges faced by their customers.


There has been a significant focus on ensuring a safe working environment for all Halma company employees. Measures taken include working from home wherever possible, a ban on non-essential travel and visitors to facilities, increased spacing between workstations, appropriate protective equipment, staggered shifts and breaks, plus enhanced cleaning processes and contingency planning.


Customer needs


In accommodating these changes, our operational teams continue to show exceptional commitment and dedication to ensure that customer needs are met and to contribute to the global fight against COVID-19 directly and indirectly. Examples include:


·    At least 10 companies from across every Halma sector are using rapid prototyping capabilities to manufacture personal protective equipment for health workers, in their local communities and nationally in the UK, Europe and the USA.

·    Alicat, Perma Pure and Maxtec are making components for ventilators and respiratory health devices for hospitals.

·    Diba and Bio-Chem are supplying parts which are used in new medical diagnostic test instruments.

·    SunTech, Riester and Cardios are supplying primary care devices to test the blood pressure and cardiac health of patients.

·    CenTrak's technology is being used in healthcare facilities and care homes to track the movement of people and ensure compliance with hand hygiene regimes.

·    BEA is making sensors, including those specifically designed for healthcare facilities, to ensure that doors can be opened and closed automatically without human contact.

·    Our water businesses including HWM, Mini-Cam, Palintest, Sensorex and UV companies are ensuring that water utilities can preserve continuity of a safe supply to homes and critical infrastructure.

·    Our fire businesses are helping to ensure that fire safety is maintained in critical infrastructure across the world.

·    One of our most recent acquisitions, Sensit, is supporting gas utilities in the USA to ensure that their residential supply pipelines are safe.


Cost reduction and cash conservation measures


As in previous downturns, we have sought to act quickly to mitigate potential impacts by reducing costs, optimising cash flow, protecting liquidity and, where necessary, changing how we operate.


These actions are expected to result in a cost reduction (net of the cost to implement them) of over £20 million in the first quarter of the new financial year, compared to the previous fourth quarter's run-rate. We will review these mitigating actions at the end of the first quarter.


We have sought to limit the impact of these actions on our employees, and protect their employment, in anticipation of trading conditions improving later in the financial year. Company, sector and group leaders have agreed to temporary salary reductions from 1 April 2020 for an initial three-month period, demonstrating their commitment to absorb a significant proportion of the cost savings necessary to protect ongoing operations. This includes the Halma plc Board and the Executive Board, both of which have agreed to a 20% reduction in salaries or fees. Whilst we have furloughed a small percentage of our workforce, currently we intend to fund this without any support from the UK government's Coronavirus Job Retention Scheme.


We have implemented a widespread hiring freeze, a reduction in the use of contractors and a significant reduction in discretionary overhead spending. We are ensuring that our companies continue to manage their working capital effectively, while maintaining productive relationships with customers and suppliers. We are limiting capital investment to essential projects and R&D only, and do not expect to complete any acquisitions during the first quarter, though our M&A search efforts are continuing.


The COVID-19 pandemic is expected to have a net adverse impact on our markets and our full year financial results to 31 March 2021, which are likely to have a significant second half weighting even though the timing and profile of recovery remains uncertain at this stage.




In what are challenging and changing times, we have taken a considerable number of actions to date and will continue to monitor matters closely. We will provide a further update in our Full Year results announcement.


Andrew Williams, Chief Executive of Halma, said:


"Through this current challenging period, many of our companies are demonstrating how they are living Halma's purpose of 'growing a safer, cleaner, healthier future for everyone, every day', by supporting the fight against COVID-19 directly and indirectly.


"Our agile business model, strong positions in markets with long-term growth drivers and the talent and dedication of our people are expected to ensure that we will perform relatively resiliently in the short term and be well positioned to resume growth as markets recover."


For further information, please contact:


Marc Ronchetti, Chief Financial Officer

+44 (0)7824 374 980

MHP Communications

Rachel Hirst

+44 (0)20 3128 8763

Andrew Jaques

+44 (0)20 3128 8769



About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner and healthier future for people worldwide. Our innovative products and solutions address many of the key issues facing the world today. We operate in four sectors: Process Safety, Infrastructure Safety, Medical and Environmental & Analysis. We employ over 7,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia-Pacific. We target global niche markets where sustainable growth and high returns are supported by long-term drivers. Halma is listed on the London Stock Exchange and has been a member of the FTSE 100 index since December 2017.




1.   Adjusted profit before tax is before amortisation and impairment of acquired intangible assets, acquisition items, restructuring costs and profit or loss on disposal of businesses.


2.   This update is based upon current management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks, including the effects of the current COVID-19 outbreak.


3.   A copy of this announcement, together with other information about Halma, may be viewed on our website www.halma.com



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Halma PLC

Price: 2259

Market: LSE
Market Cap: £8.58 billion

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...